Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Profit After Tax (2018 - 2025)

Serina Therapeutics' Profit After Tax history spans 8 years, with the latest figure at -$4.5 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 419.15% year-over-year to -$4.5 million; the TTM value through Sep 2025 reached -$18.5 million, down 325.4%, while the annual FY2024 figure was -$11.1 million, 310.67% down from the prior year.
  • Profit After Tax for Q3 2025 was -$4.5 million at Serina Therapeutics, up from -$6.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $16.6 million in Q4 2023 and bottomed at -$15.0 million in Q1 2024.
  • The 5-year median for Profit After Tax is -$2.4 million (2022), against an average of -$1.3 million.
  • The largest annual shift saw Profit After Tax surged 701.38% in 2023 before it tumbled 1005.61% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$2.2 million in 2021, then fell by 27.86% to -$2.8 million in 2022, then soared by 701.38% to $16.6 million in 2023, then crashed by 116.08% to -$2.7 million in 2024, then tumbled by 68.41% to -$4.5 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Profit After Tax are -$4.5 million (Q3 2025), -$6.5 million (Q2 2025), and -$4.8 million (Q1 2025).